Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 339, Issue 9, 1998, Pages 591-598

  Cavé, Hélène ^a   Van Der Werff Ten Bosch, Jutte ^b   Suciu, Stefan ^c   Guidal, Christine ^a   Waterkeyn, Christine ^c   Otten, Jacques ^d   Bakkus, Marleen ^b   Thielemans, Kris ^b   Grandchamp, Bernard ^a   Vilmer, Etienne ^a   Nelken, Brigitte ^e   Fournier, Martine ^e   Boutard, Patrick ^f   Lebrun, Emmanuel ^f   Méchinaud, Françoise ^g   Garand, Richard ^g   Robert, Alain ^h   Dastugue, Nicole ^h   Plouvier, Emmanuel ⁱ   Racador, Evelyn ⁱ   Ferster, Alice ^j   Gyselinck, Jan ^k   Fenneteau, Odile ^a   Duval, Michel ^a   Solbu, Gabriel ^c   Manel, Anne Marie ^l   more..

^a HÔPITAL ROBERT DEBRÉ   (France)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c EORTC DATA CENTER   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j Centre Hospitalier Universitaire   (Belgium)

^k Algemeen Kinderziekenhuis   (Belgium)

^l HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLONE CELLS; DNA, NEOPLASM; GENE REARRANGEMENT; GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REMISSION INDUCTION;

EID: 0032572924     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808273390904     Document Type: Article

References (23)

1. d'Auriol L, Macintyre E, Galibert F, Sigaux F. In vitro amplification of T cell γ gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 1989;3:155-8.
2. Macintyre EA, d'Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F. Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. J Clin Invest 1990;86:2125-35.
3. Hansen-Hagge T, Yokota S, Bartram CR. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rear-ranged T-cell receptor & chain sequences. Blood 1989;74:1762-7.
4. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia: persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 1990;323:448-55.
5. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85: 1416-34.
6. Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992;10:1879-88.
7. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993;83:412-8.
8. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196-200.
9. Yokota S, Hansen-Hagge TE, Ludwig WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991;77:331-9.
10. Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993;82:1618-25.
11. Cavé H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 1994;83:1892-902.
12. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
13. Henze G, Buchmann S, Fengler R, Hartmann R. The BFM relapse studies in childhood ALL: concepts of two multicenter trials and results after 2 1/2 years. Haematol Blood Transfus 1987;30:147-55.
14. Breit T, Wolvers-Tettero LI, Hählen K, van Wering ER, van Dongen JJ. Limited combinatorial repertoire of γδT-cell receptors expressed by T-cell acute lymphoblastic leukemias. Leukemia 1991;5:116-24.
15. Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA. Gene rearrangement in B and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 1991;78:192-6.
16. Peto J. The calculation and interpretation of survival curves. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, England: Oxford University Press, 1984:361-80.
17. Breslow N. Comparison of survival curves. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, England: Oxford University Press, 1984:381-406.
18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
19. Cox DR. Regression models and life-tables. J R Soc Stat [B] 1972;34: 187-220.
20. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997;336:317-23.
21. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995;9:321-8.
22. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550-4.
23. Shiach CR, Evans PA, Short MA, Bailey CC, Lewis IJ, Kinsey SE. Detection and accurate sizing of PCR product by automated scanning: improved detection of immunoglobulin gene rearrangements in ALL. Br J Haematol 1993;85:431-3.